ProJenX is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics that target motor neuron degenerative pathways for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. ProJenX is a MEC company creation effort in partnership with Project ALS, a nationally recognized nonprofit organization committed to ALS research. The company's first product prosetin is the first investigational drug developed by researchers at the Project ALS Therapeutics Core at Columbia as a potential treatment for ALS.